2016
Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2016, 95: 673-679. PMID: 27034176, DOI: 10.1016/j.ijrobp.2016.01.037.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyUpfront EGFR-TKIIntracranial progression-free survivalUpfront radiation therapyProgression-free survivalBrain metastasesEGFR-TKI groupEGFR-TKIEGFR-mutant NSCLCOverall survivalRadiation therapyEpidermal Growth Factor Receptor–Mutant NonDisease-specific Graded Prognostic AssessmentUpfront EGFR tyrosine kinase inhibitorsEGFR-TKI resistance mutationSmall cell lung cancerEGFR tyrosine kinase inhibitorsEGFR-TKI useMedian overall survivalSimilar overall survivalUpfront RT groupInferior overall survivalCell lung cancerMutant lung adenocarcinomaEpidermal growth factor receptor
2012
Pegylated interferon-α-2b for children with recurrent craniopharyngioma.
Yeung JT, Pollack IF, Panigrahy A, Jakacki RI. Pegylated interferon-α-2b for children with recurrent craniopharyngioma. Journal Of Neurosurgery Pediatrics 2012, 10: 498-503. PMID: 23061825, DOI: 10.3171/2012.9.peds12225.Peer-Reviewed Original ResearchConceptsMonths of treatmentGross total resectionPatient experienced recurrenceRecurrent craniopharyngiomaExperienced recurrenceSubtotal resectionComplete responseRadiation therapyUse of PIDisease 19 monthsDisease 6 monthsDisease 10 yearsInterferon α-2bStable diseaseDurable responsesIntralesional administrationCystic tumorTumor sizeTumor responseSubcutaneous injectionCystic componentFurther interventionCraniopharyngiomaRecurrenceSustained exposure